The Right To Try Bill is a new Law, which offers hope for terminally ill patients interested in trying experimental drugs that passed Phase 1 safety standards from the FDA. While encouraging, the grim reality of experimental drugs is that a large majority fail in Phase 2/3 of Clinical Trials. This is despite Pre-Clinical experiments providing evidence that these experimental drugs work in animal models. Could variable levels of Oxidative Stress in humans cause some of this failure? If true, then there may be a simple way to improve the odds of an experimental drug working for Right To Try patients. This approach should also interest Big Pharma. An Oxidative Stress Test provides feedback on lifestyle choices for lowering Oxidative Stress. This approach should be used prior to using experimental drugs for better results.
Elevated Blood Oxidative Stress May Impact Clinical Trials
The primary source of Oxidative Stress in adult Americans is from blood cells, which we call Blood Oxidative Stress or BLOS. Although about 2/3 of adult Americans are thought to suffer from elevated levels of BLOS, medical researchers do NOT control it during Clinical Trials. Control in this context means minimizing BLOS during the clinical trial. But Big Pharma has been doing this for decades and this is the right approach for evaluating experimental drugs, right?